Inhibrx Biosciences

Company snapshot

At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in

• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 35 US patent(s) indexed to this assignee profile.
• 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Inhibrx Biosciences. Not investment advice.

• deal Jun 7, 2026

  Sanofi completes Inhibrx acquisition for $1.7B

• Peer + 0 momentum

  RECURSION PHARMACEUTICALS

  TA overlap score 21.8

• Peer + 0 momentum

  Bicara Therapeutics

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Inhibrx Biosciences.

1. Jun 8, 2026 Clinical update

   Ph1 INBRX-109 Part 3 — Phase 2

2. Jun 8, 2026 Clinical update

   Ph2 INBRX-109 SA CS — Phase 2

3. Jun 8, 2026 Clinical update

   INBRX106-01-201 — Phase 3

4. Jun 5, 2026 Clinical update

   INBRX-109 — Phase 2

5. Jun 5, 2026 Clinical update

   INBRX-106 - Hexavalent OX40 agonist antibody — Phase 2

View all clinical trial activity →

• What is Inhibrx Biosciences?

  Inhibrx Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker INBX. Primary therapeutic focus areas include Unresectable or metastatic conventional chondrosarcoma, Advanced or metastatic solid tumors, Head and Neck Squamous Cell Car

• Is Inhibrx Biosciences publicly traded?

  Yes. Inhibrx Biosciences is listed with ticker INBX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Inhibrx Biosciences develop or market?

  We link 17 drug profile(s) where Inhibrx Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/inhibrx-biosciences#company-drugs.

• What are the latest developments for Inhibrx Biosciences?

  In the last 12 months our linked public records show 10 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Inhibrx Biosciences focus on?

  Inhibrx Biosciences focuses on Unresectable or metastatic conventional chondrosarcoma, Advanced or metastatic solid tumors, Head and Neck Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.